Skip to main content

Advertisement

Table 4 Laplace regression models with years to first 10% of total mortality as outcome for patients aged ≥45 years with diagnoses of AF and diabetes mellitus ( n= 2,413) attending the 75 PHCCs between January 1st2001 and December 31st2007, stratified by age: 45–79 years (n = 1,704) and 80–104 years (n = 709)

From: Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation – a cohort study from Sweden using propensity score analyses

  Patients aged <80 years Patients aged ≥80 years All patients
  Full model Full model Full model
  HR (95% CI) HR (95% CI) HR (95% CI)
Antithrombotic drugs    
  Antiplatelets vs. no treatment 0.81 (-1.24; 2.87) 1.78 (1.04; 2.52) 1.02 (-0.34; 2.39)
  Anticoagulants vs. no treatment 2.70 (0.04; 5.37) 1.22 (-0.06; 2.51) 2.20 (0.79; 3.62)
  Anticoagulants vs. antiplatelets 2.31 (0.84; 3.79) 0.23 (-1.10; 1.55) 1.21 (-0.03; 2.45)
Digitalis 1.02 (-0.26; 2.30) 0.25 (-2.35; 2.85) 0.58 (-0.28; 1.45)
Loop diuretics -2.44 (-3.79; -1.08) 0.69 (-0.89; 2.26) -1.22 (-2.79; 0.34)
Thiazides 0.18 (-1.34; 1.70) 1.09 (0.10; 2.07) 0.35 (-0.56; 1.24)
Aldosterone antagonists -0.17 (-1.23; 0.88) -0.17 (-0.89; 0.56) -0.07 (-0.90; 0.76)
Beta blockers 1.28 (-0.13; 2.69) 0.29 (-0.47; 1.06) 1.18 (0.32; 2.04)
RAS-blocking agents -0.18 (-1.40; 1.04) -0.19 (-0.74 (0.36) 0.23 (-0.57; 1.02)
Calcium receptor-blocking agents -0.02 (-1.20; 1.16) -0.07 (-0.86; 0.72) -0.54 (-1.61; 0.53)
Statins 2.11 (0.88; 3.35) 0.38 (-1.37; 2.14) 1.24 (0.38; 2.10)
  1. Full model is adjusted for a propensity score comprising sex, age group, co-morbidities, educational level, marital status and for all pharmacotherapies. HRs and 95% CIs are shown. Statistically significant HRs are highlighted in bold.